Yidu Tech (02158.HK) won the bid for the Phase III clinical research project of recombinant human nerve growth factor (SMR001) eye drops.

Zhtng Cijng APP News, Yd Kj (02158.HK) issued an announcement. Recently, the company's affiliated company, Tianjin Happy Life Technology Co., Ltd., was awarded the restructuring project of the Phase III clinical study of recombinant human nerve growth factor eye drops (SMR001) by Shandong Ynd Biotechnology Co., Ltd. The total amount of the project is approximately RMB 55,817,600.